Search results
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 9 hours agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 9 hours agoProgression-free survival is how long patients live before their cancer worsens. The company added...
Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
Pharmaceutical Technology via Yahoo Finance· 2 days agoGlobalData is the parent company of Pharmaceutical Technology. Pfizer is also seeking European...
Stock market today: gloomy start to May ahead of Fed decision
Newsweek· 16 hours agoU.S. futures were down Wednesday morning ahead of a decision by the Federal Reserve on interest...
FDA grants full approval to cervical cancer drug TIVDAK By Investing.com
Investing.com· 2 days agoFood and Drug Administration (FDA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoCOPENHAGEN, Denmark; April 30, 2024 – Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
Are Ultra-Processed Foods Really all that Unhealthy?
Scientific American· 6 days agoThe problem, according to this increasingly popular argument, is that we’re eating lots of ultra-processed food or UPF. Traditionally, people used...
This Is How Denim Brands Are Paving the Sustainable Way
Elle via Yahoo News· 8 hours agoDenim brands enthusiastically experiment with sustainability, improving processes more and more...
New mRNA cancer vaccine triggers fierce immune response to fight malignant brain tumor
Medical Xpress· 12 hours agoThe results mirror those in 10 pet dog patients suffering from naturally occurring brain tumors...
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - G1...
Benzinga· 16 hours ago- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results